On Demand
Enabling SEDDS Formulation Choice through In Vitro-In Vivo Correlation
for high throughput screening of SEDDS formulations in vitro to predict in vivo ranking.
SEDDS formulations consist of complex mixtures of lipid-surfactant agents in order to match the target interfacial tension.
The absorption rate of the Active Pharmaceutical Ingredient (API) can be enhanced by fine tuning the composition of SEDDS.
In this webinar, you can learn the steps BASF took, in partnership with Pion, in developing enhanced SEDDS formulations based on their surfactant emulsion properties, including droplet size and hydrophilicity. BASF generated in vitro information via Pion technology, and as a result, were able to report enhanced IVIVC performance for SEDDS formulations.
Pion’s instruments fill the existing gap between in vitro experiments and their in vivo validation. BASF SEDDS formulations showed an excellent In vitro – in vivo correlation (IVIVC). The Pion MacroFLUX™ is used for conducting simultaneous dissolution-absorption studies. Such studies allow assessment of the complex interplay between solubility, permeability and dissolution rate in-vitro and provide valuable tools for understanding in vivo outcomes.
SEDDS Formulations
- SEDDS are suited to the conditions encountered in the gastrointestinal tract while also being able to increase solubility and bioavailability of lipophilic drugs.
- SEDDS can be utilized within a soft gel formulation or liquid oral formulation.
Enhanced predictive outcomes
- Enhanced IVIVC performance significantly reduce the number of studies required during formulation development, increase quality, and reduce regulatory limitations.
IVIV correlation (IVIVC)
- Excellent IVIVC were obtained by BASF SEDDS formulations across different chemistry sets (i.e., GMO- and Capmul).
BASF excipients
- BASF surfactants are highly effective in preparing stable and robust SEDDS formulations, which have shown an excellent IVIVC with the MacrofluxTM membranes.